Advertisement

Immediate vs. Delayed ADT for Recurrent Prostate Cancer

  • Tae Heon Kim
  • Seong Il Seo
Chapter

Abstract

Despite high cure rates with radical prostatectomy or radiation therapy for localized prostate cancer, approximately 30% of men experience a rising prostate-specific antigen (PSA) level, a condition known as biochemical recurrence (BCR) [1–3]. Elevations in PSA may indicate local or distant recurrence. Thus, once BCR occurs the patient is presumed to have recurrent prostate cancer. Among patients who develop BCR, approximately one-third will develop clinical recurrence within 8 years from BCR [4]. Depending on the type of initial local therapy, reasonable options for BCR patients include observation with close surveillance, salvage radical prostatectomy, salvage radiation therapy, androgen deprivation therapy (ADT), and enrollment in investigational clinical trials. Of these options, ADT has long been accepted and widely used as an effective treatment for patients with advanced, recurrent, and disseminated prostate cancer, but it is associated with disadvantages including side effects as well as substantial cost. Not all patients with recurrent prostate cancer have the same prognosis, and understanding clinical factors that affect developing metastatic disease is crucial. Clinicians must balance a patient’s competing benefit of survival gain and potential risk of an increased morbidity and impair quality of life. The trade-off between the relative benefits and harms of ADT in patients with recurrent prostate cancer is essential for consideration regarding in whom, how, and when it should be used. One of the most prominent questions in the treatment of patient with recurrent prostate cancer is that whether to initiate ADT immediately upon an increasing PSA level or to delay its use until the development of symptomatic or radiographic progression occurs. Despite the proven efficacy of ADT in recurrent prostate cancer, consensus as to the optimal time to initiate ADT remains in debate because results from clinical trials are mixed.

References

  1. 1.
    Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68(3):593–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37(5):1035–41.Google Scholar
  8. 8.
    Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605.CrossRefPubMedGoogle Scholar
  10. 10.
    Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA. Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am. 2013;27(6):1205–19, viiiCrossRefPubMedGoogle Scholar
  11. 11.
    Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology. 2001;58(2 Suppl 1):94–100.CrossRefPubMedGoogle Scholar
  12. 12.
    Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112(10):2188–94.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.CrossRefPubMedGoogle Scholar
  15. 15.
    Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015;51(7):817–24.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol. 2008;179(5):1830–7, discussion 7CrossRefPubMedGoogle Scholar
  17. 17.
    Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17(6):727–37.CrossRefPubMedGoogle Scholar
  18. 18.
    Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017;18(9):1192–201.CrossRefPubMedGoogle Scholar
  19. 19.
    Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171(3):1141–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer. 2003;97(4):1127–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Klayton TL, Ruth K, Buyyounouski MK, Uzzo RG, Wong YN, Chen DY, et al. PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT Or IMRT using the phoenix definition. Pract Radiat Oncol. 2011;1(4):235–42.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of UrologySamsung Medical Center, Sungkyunkwan University School of MedicineSeoulSouth Korea

Personalised recommendations